RxDoctor Payments Data

Waheed Akhtar, MD

Cardiovascular Disease · Goldsboro, NCNPI 1477530863

Payments from drug & device makers

$1,375in general payments, 2019–2025

Across 80 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Boston Scientific$107
  • Abbott$92
  • Irhythm Technologies, Inc.$70
  • Kestra Medical Technology Services, Inc.$35
  • Bayer$22
  • plus $38 from 3 others

What the payments were for

  • Food & beverage$1,375100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,375 in reported general payments places this provider in the 35th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$490,119
Medicare patients
1,518
Services billed
9,946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban725$601,840
XareltoRivaroxaban57$57,311
Repatha SureclickEvolocumab27$42,166
JardianceEmpagliflozin32$37,301
EntrestoSacubitril/Valsartan19$18,901
Metoprolol Succinate1,111$11,277
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine47$7,991
BrilintaTicagrelor14$6,627
Ranolazine ErRanolazine87$5,457
Amiodarone Hcl239$4,685
Diltiazem 24hr Er (Cd)Diltiazem Hcl216$4,586
SymbicortBudesonide/Formoterol Fumarate17$4,554
Spironolactone615$3,618
Isosorbide Dinitrate15$3,501
SotalolSotalol Hcl278$3,471

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$13$18,90119 claims
AstraZenecaBrilinta, Symbicort$15$11,18131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Goldsboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →